Critical Therapeutics, Cornerstone to merge

Critical Therapeutics is merging with Cornerstone BioPharma Holdings, a specialty pharmaceutical company that develops treatments for respiratory disorders. Critical Therapeutics is also developing respiratory drugs, along with inflammatory and critical care treatments. Trevor Phillips, Critical's CEO, said the new company would be focused on respiratory diseases. 

"After reviewing alternatives during a strategic review process over the past six months, we believe that the product synergies created by a merger with Cornerstone offer the best opportunity to drive stockholder value," said Phillips. The stock-for-stock transaction is targeted to close in the fourth quarter of 2008.

- here's the merger release

Related Articles:
Critical Therapeutics shares soar on asthma approval
Critical Therapeutics slashes staff in restructuring
Critical Therapeutics compound fails in Phase II
Critical Therapeutics raising $54M

Suggested Articles

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.

RA Capital 's 15-month old inaugural venture fund that has already seen 25% of its portfolio companies IPO or be acquired.